$1.610
0.000 (0.00%)At close
BMRA News
BMRA Events
Biomerica Files $250M Mixed Securities Shelf
Biomerica files $250M mixed securities shelf
Selling Stockholders Plan to Sell 1.4M Shares of Common Stock
This filing relates to the offer and sale from time to time by the selling stockholders of up to 1.4M shares of common stock. The company is not selling any shares under this prospectus and will not receive any of the proceeds from the sale of shares by the selling stockholders.
Biomerica Engages B. Riley as Financial Advisor
Biomerica announced that it has engaged B. Riley as its exclusive financial advisor in connection with the evaluation and potential pursuit of potential strategic opportunities. Under the engagement, B. Riley may assist the company in reviewing, evaluating and negotiating potential acquisitions, mergers, joint ventures, partnerships, spin-offs and other strategic combinations.
Biomerica Completes Private Placement of 1,393,705 Shares, Raising Approximately $2.23M
Biomerica announced that it has entered into definitive agreements with institutional and individual investors for a private placement of 1,393,705 unregistered shares of the company's common stock at a price of $1.60 per share, expected to provide approximately $2.23M in gross proceeds to the company. The financing was priced at $1.60 at the time the definitive agreements were entered into and includes no warrants or discounted securities. Participation in the financing included B. Riley Principal Capital , certain executives and employees of B. Riley Securities, the company's Chief Executive Officer, and all members of the company's Board of Directors, reflecting meaningful alignment between outside investors and company leadership. Following the closing of the financing, the company expects to have approximately 4,588,968 shares of the company's common stock outstanding on a pro forma basis, with the shares issued in the financing representing approximately 30.4% of pro forma shares outstanding. The company intends to use the proceeds to strengthen its balance sheet and fund operations as its Board of Directors continues to evaluate a range of potential strategic opportunities intended to maximize shareholder value.
Biomerica Enters Service Agreement with Life Sciences Company, Contract Exceeds $1.75M
Biomerica announced it has entered into a master services agreement with a confidential life sciences company to develop proprietary in vitro diagnostic assays. The engagement carries an initial contract development target fee of over $1.75M, to be earned across multiple statements of work under the MSA. Biomerica was chosen following a competitive evaluation in which multiple CDMO organizations were assessed. The MSA establishes an initial three-year term with automatic one-year renewals. All development work will be performed at Biomerica's FDA-licensed, ISO 13485-certified facility in Irvine, California. Revenue will be recognized on a milestone-completion basis as individual SOW deliverables are accepted.
Related articles
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.